

B1 8. The method of Claim 1, wherein the fumonisin analog is selected from the group consisting of Fumonisins B₁ and AAL toxin.

B2 Sub C3 17. The method of Claim 9, wherein the fumonisin is selected from the group consisting of Fumonisins B₁ and Fumonisins B₂. *No Support*

18. The method of Claim 9, wherein the fumonisin analog is selected from the group consisting of Fumonisins B₁ and AAL toxin.

not fumonisins analog.

REMARKS

No Support.

Response to Restriction Requirement

The Examiner has restricted the prosecution of the present application to Group I (claims 1-18), Group II (claims 27 and 28), Group III (claims 29 and 30) or Group IV (claims 37 and 38). Applicants confirm the election of the claims of Group I, without traverse.

The claims of Group I are directed a method of altering the metabolism of sphingolipids in a cell. The Examiner has also requested that the Applicants elect a single disclosed species. Applicants elect the species Fumonisin B₁.

Respectfully submitted,

Sherry Knowles

Sherry M. Knowles
Registration No. 33,052

KING & SPALDING
191 Peachtree Street
Atlanta, Georgia 30303
Telephone: 404-572-3541
Facsimile: 404-572-5145